09Jun 2023
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Gefapixant, a P2X3 receptor antagonist, has shown effectiveness in treating refractory chronic cough (RCC) and unexplained chronic cough (UCC) in two phase III trials called COUGH-1 and COUGH-2. This analysis presents patient-reported outcome (PRO) data evaluating the long-term benefits and safety of gefapixant over 52 weeks. The results show that participants receiving gefapixant 45 mg twice daily experienced clinically meaningful improvements in PROs compared to those receiving a placebo. However, taste-related adverse events were more common in the gefapixant group, leading to discontinuation in some cases. Most taste-related adverse events resolved either after discontinuation or while still receiving gefapixant. Overall, gefapixant appears to be an effective and durable treatment for RCC and UCC.

  • #critical care

Like

Save

Share